Physician profile
Michael Borenitsch
NPI 1407207376
$866.17
in general payments reported to CMS, 2019-2025
16 companies · $44.40 in 2025
The $44.40 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $76.70 · 2022: $62.30 · 2024: $21.21 · 2025: $44.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $65.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $65.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $231.42 | 2019 | |
| Novo Nordisk INC | $147.75 | 2019-2025 | Ozempic, Rybelsus |
| Mylan Specialty L.P. | $121.16 | 2019 | |
| Amgen INC. | $72.68 | 2019-2020 | |
| Glaxosmithkline, LLC. | $45.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.44 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $37.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.32 | 2019-2020 | |
| Allergan, INC. | $23.94 | 2019 | |
| Dexcom, INC. | $19.70 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.10 | 2019 | |
| Astellas Pharma US INC | $18.16 | 2019 | |
| Alfasigma USA, INC. | $16.63 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.12 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.59 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Borenitsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.